SEQUENT SCIENTIFIC
|
|
BOM : 512529     NSE : SEQUENT     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 10,2025 |
Price(EOD): ₹ 144.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 3,626.85 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SEQUENT SCIENTIFIC | -1.2% | -11.1% | 19.9% |
SUN PHARMACEUTICAL INDUSTRIES | 2.8% | -7.5% | 2.3% |
DIVIS LABORATORIES | -0.2% | -9.9% | 60.4% |
CIPLA | 4.4% | -0.6% | -1% |
TORRENT PHARMACEUTICALS | 4.8% | -2.9% | 15.4% |
DR REDDYS LABORATORIES | NA | -9.4% | -10.2% |
MANKIND PHARMA | -0.7% | -8.8% | 7.1% |
ZYDUS LIFESCIENCES | 2.5% | -11.4% | -5.5% |
LUPIN | 2.9% | -8.1% | 20.9% |
FUNDAMENTAL ANALYSIS OF SEQUENT SCIENTIFIC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SEQUENT SCIENTIFIC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
156.64
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 23.15 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 6.26
P/B Calculated based on Book Value of Rs 579.25 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.4
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,510.87 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
34% -4% -7% |
SHARE PRICE MOMENTUM OF SEQUENT SCIENTIFIC
SEQUENT SCIENTIFIC vs SENSEX
DEBT OF SEQUENT SCIENTIFIC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.05 0.02 0.02 0.03 |
0.78 0.62 0.49 0.63 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SEQUENT SCIENTIFIC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SEQUENT SCIENTIFIC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
6.01% -11.76% 2.53% 2.21% |
18.66% 55.06% 443.62% -39.33% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
SEQUENT SCIENTIFIC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE SMALLCAP | 4.4% | -11.6% | -1.9% |
BSE ALLCAP | 3.1% | -6.1% | -0.2% |
BSE MIDSMALLCAP | 3% | -10.5% | -1.8% |
BSE HEALTHCARE | 2.2% | -9% | 12.8% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MICROCAP 250 | 6.7% | -8.7% | 1.4% |
NIFTY MIDSMALL HEALTHCARE | 3.8% | -6.4% | 17.4% |
NIFTY TOTAL MARKET | 3% | -6% | 0.1% |
You may also like the below Video Courses
FAQ about SEQUENT SCIENTIFIC
Is SEQUENT SCIENTIFIC good for long term investment?
As on Mar 10,2025, the Fundamentals of SEQUENT SCIENTIFIC look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SEQUENT SCIENTIFIC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SEQUENT SCIENTIFIC UnderValued or OverValued?
As on Mar 10,2025, SEQUENT SCIENTIFIC is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of SEQUENT SCIENTIFIC ?
As on Mar 10,2025, the Intrinsic Value of SEQUENT SCIENTIFIC is Rs. 151.04 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 108.23
Fair Value [Median EV / Sales Model] : Rs. 151.04
Fair Value [Median Price / Sales Model] : Rs. 155.84
Estimated Median Fair Value of SEQUENT SCIENTIFIC : Rs. 151.04
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.